SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

Incannex Healthcare Inc

Incannex Healthcare Limited - ADR

Incannex Healthcare is trending due to a new institutional offering at $5 per share and the termination of its ATM facility, although investor sentiment is sharply divided over news of an unexpected additional Phase 2 study pushing IHL-42X's Phase 3 trial start to late 2027, even as NASDAQ compliance is achieved. While many are furious about prolonged timelines and perceived management actions, others view the institutional backing and ATM termination as stabilizing factors for the biotech's pipeline.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending after CEO Alex Karp's CNBC appearance highlighted AI weapons and defensive products. This coincides with major new partnerships with Nvidia for sovereign AI OS and Ondas for multi-domain intelligence platforms, driving community discussion on its critical and expanding role in defense and enterprise AI.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as the community buzzes about the enrollment of the first patient in its Phase 2 trial for SLS009 in first-line AML, building on impressive early survival data. This catalyst, coupled with the nearing completion of the REGAL Phase 3 for GPS and a strengthened balance sheet from recent warrant exercises, amplifies discussions of the company as a multi-asset contender in AML with potential for strategic partnerships.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as the community eagerly awaits its live product demonstrations and Lightwave Award at the upcoming OFC Conference, fueling speculation around new partnerships and substantial orders for its optical interconnect technology, especially following Marvell's optimistic projections for Celestial AI's photonic fabric, which incorporates POET's solutions.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath (PATH) is trending as its strong Q4 earnings beat, GAAP profitability, and a new $500 million share buyback are met with mixed investor reactions due to modest forward growth guidance and several analyst price target reductions. The community is actively debating the company's strategic shift to 'Agentic AI' and potential government contracts against concerns about its growth trajectory in a competitive automation market.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas (ONDS) is trending following a strategic partnership with Palantir and the acquisition of BIRD Aerosystems, which significantly expands its AI-enabled multi-domain defense capabilities and generates immense buzz about its future in the defense sector. While many in the community are bullish, anticipating a major short squeeze and substantial growth, others remain cautious, citing concerns over dilution and the stock's muted reaction to the otherwise significant news.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is trending due to a rapid price surge that has the community questioning its immediate catalyst, with many speculating on a gamma squeeze and unusual options activity. This momentum is widely attributed to Himax's role as a key supplier for NVIDIA's Co-Packaged Optics (CPO) initiatives, alongside positive movement from its CPO partner FOCI, underscoring its position in the silicon photonics market for AI data centers.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending as escalating tensions and reported tanker attacks in the Strait of Hormuz fuel significant concerns over global oil supply, leading to a sharp community divide between bulls anticipating much higher prices and bears expecting a swift market correction despite strategic reserve releases.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is trending after announcing a development agreement with Tower Semiconductor, a major silicon photonics foundry, to integrate its electro-optic polymer modulators. The community views this as a critical validation, believing it could embed LWLG's technology into key supply chains for high-speed AI data centers and accelerate broader industry adoption of its polymer solutions.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace is trending following its successful Alpha Flight 7 mission, which delivered a Lockheed Martin payload and validated Block II upgrades, sparking widespread bullish sentiment and discussions of a significant comeback for the commercial space company after prior setbacks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fortress Biotech (NASDAQ:FBIO) Stock Passes Above Two Hundred Day Moving Average - Here's Why

Fortress Biotech (NASDAQ:FBIO) Stock Passes Above 200 Day Moving Average - Should You Sell...

<ul class="summary-bullets"><li>The unit is selling the voucher for $205 million, the company said.&nbsp;</li><li>20% of the proceeds from the voucher sale is owed to the Eunice Kennedy Shriver National Institute of Child Health and Human Development.&nbsp;</li><li>The voucher was issued upon approval of ZYCUBO last month for the treatment of Menkes disease, a rare genetic disorder, in pediatric patients.</li></ul>Shares of Fortress Biotech, Inc. (FBIO) rose 10% on Monday after the company announced that its majority-owned unit will sell its voucher for expedited review of a drug application by the U.S. Food and Drug Administration (FDA) for $205 million.Fortress <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/02/23/3242714/28889/en/UPDATE-Fortress-Biotech-s-Subsidiary-Cyprium-Therapeutics-Enters-into-Agreement-to-Sell-Rare-Pediatric-Disease-Priority-Review-Voucher-for-205-Million.html">said</a> that its unit Cyprium Therapeutics, Inc. has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Sentynl Therapeutics, Inc, a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences Limited.Twenty percent of the proceeds from the voucher sale is owed to the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the company said, while also noting that the transaction is subject to customary closing conditions.The PRV program aims to incentivize drug development for rare pediatric diseases.<h2 class="st-heading-2">Cyprium, Sentynl History</h2>Sentynl took over responsibility for the development and commercialization of the drug ZYCUBO from Cyprium in December 2023. Zycubo was approved by the FDA in January for the treatment of Menkes disease, a rare genetic disorder, in pediatric patients. The voucher was issued upon approval of ZYCUBO.Fortress said on Monday that it remains eligible to receive tiered royalties on net sales of ZYCUBO and up to $129 million in aggregate development and sales milestones from Sentynl.“With the PRV sale and three FDA approvals received in the last 15 months for Emrosi, UNLOXCYT, and ZYCUBO, in addition to the recent sale of our former subsidiary Checkpoint Therapeutics to Sun Pharma, we believe that we are well positioned to continue to execute on our portfolio,” said Fortress CEO Lindsay A. Rosenwald.<h2 class="st-heading-2">Cyprium’s Pipeline</h2>Menkes disease is a rare genetic disorder leading to impaired copper transport throughout the body. It causes low copper levels in the brain, resulting in rapid neurodegeneration, seizures, and more. Cyprium is also developing a gene therapy to deliver working copies of the copper transporter that is defective in patients with Menkes disease, and to be used in combination with ZYCUBO. The gene therapy is currently in pre-clinical development.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around FBIO shares jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.A Stocktwits user expressed optimism for the gene therapy trial data sending the stock skyrocketing. In the short term, the user expects the company to be buoyed by royalties from its Menkes drug, and in the long term, from the gene therapy.<stembedurl>https://www.stocktwits.com/buymoremakemore/message/645614222</stembedurl><a href="https://stocktwits.com/symbol/FBIO">FBIO stock</a> has more than doubled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/gossamer-bio-stock-plummeted-today-what-is-behind-the-crash/cZRtwTVR4ym">Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Fortress Biotech logo is displayed on the screen of a tablet.

FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy 

Fortress said that its majority-owned unit Cyprium Therapeutics has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sentynl Therapeutics. 

Equity

Fortress said that its majority-owned unit Cyprium Therapeutics has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sentynl Therapeutics. 


Fortress Biotech's (FBIO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated a "buy" rating and issued a $17.00 price objective on shares of Fortress Biotech in a research report on Monday...

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - Here's What Happened

Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200-Day Moving Average - Time to Sell...

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - What's Next?

Fortress Biotech (NASDAQ:FBIO) Share Price Passes Above 200-Day Moving Average - Here's Why...

Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes

CI's Q4 adjusted EPS beats estimates as Evernorth growth and higher specialty volumes offset fewer medical customers and elevated costs.

Fortress Biotech (NASDAQ:FBIO) Shares Pass Above 200-Day Moving Average - What's Next?

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - Time to Sell...

Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums

ELV tops Q4 EPS estimates as premiums grow and Carelon revenues surge, even as medical membership slips and expenses climb.

Centene Expands Palliative Care Access in Ohio Through Tuesday Health

CNC teams up with Tuesday Health to expand palliative care in Ohio, blending in-person and virtual support.

Zacks Research Upgrades Fortress Biotech (NASDAQ:FBIO) to Strong-Buy

Zacks Research upgraded shares of Fortress Biotech from a "hold" rating to a "strong-buy" rating in a research report on Wednesday...

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

FBIO
Fortress Biotech Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FBIO News

FBIOFortress Biotech Inc